# Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

> **NCT04915248** · PHASE2 · RECRUITING · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 28 (estimated)

## Conditions studied

- Plasmablastic Lymphoma

## Interventions

- **DRUG:** Daratumumab
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04915248
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-11
- **Primary completion:** 2026-01-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04915248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04915248, "Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04915248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*